Lori Kunkel
Director/Board Member presso ORIC PHARMACEUTICALS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Lori Anne Kunkel is currently an Independent Director at Nurix Therapeutics, Inc., Oric Pharmaceuticals, Inc., K36 Therapeutics, Inc., and Enliven Therapeutics, Inc. She is also the Owner of Lak505, LLC.
Previously, Dr. Kunkel held positions such as Associate Director-Clinical Development at Chiron Corp., Independent Director at Curis, Inc., Director at Tocagen, Inc., Director at Loxo Oncology, Inc., Director at Amphivena Therapeutics, Inc., Director at Harpoon Therapeutics, Inc., Director at Maverick Therapeutics, Inc., Head-Clinical Scientist at Genentech, Inc., Chief Medical Officer at Pharmacyclics LLC, Vice President-Medical Affairs at Genitope Corp., Vice President-Clinical Development at Xencor, Inc., Chief Medical Officer at Syndax Pharmaceuticals, Inc., Chief Medical Officer at Proteolix, Inc., and Chief Medical Officer at ACT Biotech, Inc. She also held positions at Onyx Pharmaceuticals, Inc., XOMA Corp., ZymoGenetics, Inc., Salmedix, Inc., and DNAX Research, Inc. Additionally, she was a Member of the Bone Marrow Transplant Unit at the University of California.
Dr. Kunkel obtained a doctorate degree from the University of Southern California and an undergraduate degree from the University of California San Diego.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 08/04/2024 | 45 926 ( 0.11% ) | 807 838 $ | 31/03/2024 | |
NURIX THERAPEUTICS, INC.
0.11% | 21/03/2024 | 54 027 ( 0.11% ) | 794 197 $ | 31/03/2024 |
ORIC PHARMACEUTICALS INC
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Lori Kunkel
| Società | Posizione | Inizio |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Director/Board Member | 01/07/2019 |
| ORIC PHARMACEUTICALS, INC. | Director/Board Member | 09/06/2020 |
| ENLIVEN THERAPEUTICS, INC. | Director/Board Member | 09/04/2024 |
K36 Therapeutics, Inc.
 K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Director/Board Member | - |
| Lak505, LLC | Corporate Officer/Principal | 01/04/2012 |
Precedenti posizioni note di Lori Kunkel
| Società | Posizione | Fine |
|---|---|---|
| CURIS, INC. | Director/Board Member | 30/09/2022 |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Director/Board Member | 01/08/2021 |
| FORTE BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 15/04/2019 |
| LOXO ONCOLOGY INC | Chief Tech/Sci/R&D Officer | 01/08/2013 |
| ░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formazione di Lori Kunkel
| University of Southern California | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 8 |
|---|---|
| XOMA CORPORATION | Health Technology |
| CURIS, INC. | Health Technology |
| XENCOR, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| HARPOON THERAPEUTICS, INC. | Health Technology |
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Aziende private | 16 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Genitope Corp.
 Genitope Corp. BiotechnologyHealth Technology Genitope Corp. operates as a biotechnology company, which focuses on the research and development of novel immunotherapies for the treatment of cancer. The company was founded on August 15, 1996 and is headquartered in Redwood, CA. | Health Technology |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
| DNAX Research, Inc. | |
ACT Biotech, Inc.
 ACT Biotech, Inc. Pharmaceuticals: MajorHealth Technology ACT Biotech, Inc. operates as a biopharmaceutical company which develops and commercializes targeted oral cancer drugs. The company was founded on February 15, 2008 and is headquartered in New York, NY. | Health Technology |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Health Technology |
| Lak505, LLC | |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Health Technology |
- Borsa valori
- Insiders
- Lori Kunkel
